MeMed raises USD 93 million in Series E Financing
MeMed has completed a USD 93 million Series E funding from new and existing investors.
The Israeli company recently received FDA approval for its MeMed BV test to help healthcare providers distinguish between bacterial and viral infections.
The investors include Horizons Ventures, Shavit Capital, Social Capital, La Maison Partners, Touchwood Capital, Caesarea Medical Holdings, Union Tech Ventures, ClaI Insurance, Phoenix Insurance, Poalim Equity, and Western Technology Investment. Read more here.
Naschitz Brandes Amir acts for longstanding client, MeMed. which develops diagnostic solutions to translate the immune system’s complex signals. Partner Arnon Samburski and associate Mayrav Danor advised.
MeMed was founded in 2009 by Eden and Kfir Oved, who serves as CTO and Chairman. The company employs 100 people in Israel, Europe and the U.S., with the majority being headquartered in Haifa.
